Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 1, 2006, Pages 86-90

  Mori, Kiyoshi ^a   Kamiyama, Yukari ^a   Kondo, Tetsuro ^a   Kano, Yasuhiko ^a   Kodama, Tetsuro ^a  

^a TOCHIGI CANCER CENTER   (Japan)

Author keywords

Carboplatin; Paclitaxel; Second line chemotherapy; Small cell lung cancer; Weekly chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LUNG SMALL CELL CANCER; MALE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE;

EID: 33646014424     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0114-4     Document Type: Article

References (17)

1. Ando M, Kobayashi K, Yoshimura A, Kurimoto F, Seike M, Nara M, et al (2004) Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44:121-127
2. Einhorn LH, Pennington K, McClean J (1990) Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 17:32
3. Glisson BS (2003) Recurrent small cell lung cancer. Update. Semin Oncol 30:72
4. Goto K, Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Matsumoto T, et al (2004) Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 91:659-665
5. Groen HJ, Fokkema E, Biesma B, Kwa B, van Putten JW, Postmus PE, et al (1999) Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol 17:927-932
6. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613
7. Kubota K, Nishiwaki Y, Kakinuma R, Hojo F, Matsumoto T, Ohmatsu H, et al (1997) Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15:292-296
8. Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, et al (2003) Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: eastern cooperative oncology group trial 1597. J Clin Oncol 21:1550-1555
9. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229
10. Naka N, Kawahara M, Okishio S, Hosoe S, Ogawara M, Atagi S, et al (2002) Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 37:319-323
11. Neubauer M, Schwartz J, Caracandas J, Conkling P, Ilegbodu D, Tuttle T, et al (2004) Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern cooperative oncology group performance status of 2, or age? 70 years. J Clin Oncol 22:1872-1877
12. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91
13. Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH (2001) Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-A phase III trial of the Eastern cooperative oncology group. J Clin Oncol 19:2114-2122
14. Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, et al (2003) Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer. JCOG 9507. Br J Cancer 88:808-813
15. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE (1998) A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77:347-351
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
17. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658